Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.40 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.40 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.40 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.40 |
| ▸ | TK2 | O00142 | 4/20 | 0.38 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.35 |
| ▸ | PRKCA | P17252 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5566818 | 1.00 | SLC28A1 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3TK2 | |
| SCHEMBL28649290 | 1.00 | SLC28A1 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3TK2 | |
| SCHEMBL2984128 | 1.00 | SLC28A1 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3TK2 | |
| SCHEMBL28181052 | 1.00 | SLC28A1 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3TK2 | |
| SCHEMBL2995481 | 0.96 | SLC28A1 (0.41) | SLC28A1SLC28A2SLC29A1SLC28A3TK2 | |
| SCHEMBL5566803 | 0.94 | SLC28A1 (0.36) | SLC28A1SLC28A2SLC29A1SLC28A3TK2 | |
| SCHEMBL5567272 | 0.92 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL15531959 | 0.87 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL15346466 | 0.85 | P2RY6 (0.38) | TK2 | |
| SCHEMBL25402419 | 0.83 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070160554-A1 | Acyl ribonucleosides and acyl deoxyribonucleosides, compositions of, and methods of making same | COGNIS IP MANAGEMENT GMBH (DE) | 2007-07-12 | — | — | US | claimed |
| EP-1680435-A1 | ACYL RIBONUCLEOSIDES AND ACYL DEOXYRIBONUCLEOSIDES | Cognis IP Management GmbH (DE) | 2006-07-19 | — | — | EP | claimed |
| WO-2005049633-A1 | ACYL RIBONUCLEOSIDES AND ACYL DEOXYRIBONUCLEOSIDES | COGNIS IP MANAGEMENT GMBH (DE) | 2005-06-02 | — | — | WO | claimed |
| EP-0257378-A1 | Pyrimidine derivatives, their preparation and medicaments containing these derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1988-03-02 | — | — | EP | claimed |
| US-20070160554-A1 | Acyl ribonucleosides and acyl deoxyribonucleosides, compositions of, and methods of making same | COGNIS IP MANAGEMENT GMBH (DE) | 2007-07-12 | — | — | US | disclosed |
| EP-1680435-A1 | ACYL RIBONUCLEOSIDES AND ACYL DEOXYRIBONUCLEOSIDES | Cognis IP Management GmbH (DE) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005049633-A1 | ACYL RIBONUCLEOSIDES AND ACYL DEOXYRIBONUCLEOSIDES | COGNIS IP MANAGEMENT GMBH (DE) | 2005-06-02 | — | — | WO | disclosed |
| EP-0257378-A1 | Pyrimidine derivatives, their preparation and medicaments containing these derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1988-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070160554-A1 | Acyl ribonucleosides and acyl deoxyribonucleosides, compositions of, and methods of making same | RNASEL, RNASEH1, DUT | SLC28A1 1568/4885SLC28A2 1262/4885SLC29A1 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.